Therapy Persistence

Ongoing analyses of treatment patterns after diagnosis are providing real-world evidence on treatment switches and discontinuations in different subgroups of patients.

Key Data:

GARFIELD-AF provides assessments on unselected population groups who are followed for a minimum of 2 years and a maximum of 8 years. Persistence with ongoing anticoagulant therapy is being evaluated using the following parameters.

Rate of discontinuation
Duration of time on therapy
Reasons for discontinuation

Key Publications:

Kakkar AJ et al (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J, 163, 13-19